2023-505121-14-00招募中3 期
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 320
- 试验地点
- 62
- 主要终点
- IGA score of 0 or 1 and a ≥2-grade improvement from baseline at Week 16.
研究概览
简要总结
To evaluate the efficacy of JNJ-77242113 compared with placebo in participants with moderate to severe plaque psoriasis.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •≥18 years of age at the screening visit.
- •Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention.
- •Total BSA ≥10% at screening and baseline.
- •Total PASI ≥12 at screening and baseline.
- •Total IGA ≥3 at screening and baseline.
排除标准
- •Nonplaque form of psoriasis.
- •Current drug-induced psoriasis.
- •A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
- •Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention.
- •Major surgical procedure, within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study.
结局指标
主要结局
IGA score of 0 or 1 and a ≥2-grade improvement from baseline at Week 16.
IGA score of 0 or 1 and a ≥2-grade improvement from baseline at Week 16.
PASI 90 at Week 16.
PASI 90 at Week 16.
次要结局
未报告次要终点
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (62)
Loading locations...
相似试验
招募中
3 期
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis.2024-515706-77-00Janssen Cilag International399
进行中（未招募）
3 期
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT06934226Janssen Research & Development, LLC752
进行中（未招募）
3 期
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT06095115Janssen Research & Development, LLC684
进行中（未招募）
3 期
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)Plaque PsoriasisNCT06220604Janssen Research & Development, LLC731
进行中（未招募）
3 期
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT06143878Janssen Research & Development, LLC774